- $26.09m
- $31.29m
- $13.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.79 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.29% | ||
| Return on Equity | -93.03% | ||
| Operating Margin | -25.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.66 | 11.18 | 12.27 | 13.9 | 13.07 | n/a | n/a | 6.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Radnostix, Inc. is a manufacturer of radioisotope-focused products for medical, industrial, and research applications. The Company's segments include Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. Theranostics Products segment produces an FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and thyroid cancer; radiochemicals for multiple uses in clinical research and life sciences, and cGMP API supply for third party theranostics clients. Cobalt Products segment produces a variety of cobalt-60 products. Medical Devices segment sells various third-party products and is developing its own products for commercial use. Calibration & Reference Products segment manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under the Company's RadQual brand.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 1st, 1995
- Public Since
- August 14th, 1997
- No. of Shareholders
- 476
- No. of Employees
- 44
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 529,154,204
- Address
- 4137 Commerce Circle, IDAHO FALLS, 83401
- Web
- https://radnostix.com
- Phone
- +1 2085245300
- Contact
- David Drewitz
- Auditors
- Haynie & Co.
Latest News for INIS
Upcoming Events for INIS
Q3 2026 RADNOSTIX, INC. Earnings Release
Q4 2026 RADNOSTIX, INC. Earnings Release
Similar to INIS
Acusphere
Pink Sheets on Nasdaq
Adaptimmune Therapeutics
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Allied
Pink Sheets on Nasdaq
FAQ
As of Today at 22:52 UTC, shares in RADNOSTIX are trading at $0.05. This share price information is delayed by 15 minutes.
Shares in RADNOSTIX last closed at $0.05 and the price had moved by -15% over the past 365 days. In terms of relative price strength the RADNOSTIX share price has underperformed the S&P500 Index by -23.91% over the past year.
There is no consensus recommendation for this security.
Find out moreRADNOSTIX does not currently pay a dividend.
RADNOSTIX does not currently pay a dividend.
RADNOSTIX does not currently pay a dividend.
To buy shares in RADNOSTIX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.05, shares in RADNOSTIX had a market capitalisation of $26.09m.
Here are the trading details for RADNOSTIX:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INIS
Based on an overall assessment of its quality, value and momentum RADNOSTIX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RADNOSTIX. Over the past six months, its share price has underperformed the S&P500 Index by -38.49%.
As of the last closing price of $0.05, shares in RADNOSTIX were trading -29.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RADNOSTIX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RADNOSTIX's management team is headed by:
- Christopher Grosso - NEC
- Steve Laflin - CEO
- Matthew Cox - CFO
- Robert Atcher - IND